Stryker OP-1 royalties
This article was originally published in The Gray Sheet
Curis enters agreement eliminating all future royalties to Stryker related to osteogenic protein-1 sales, the firms say Oct. 1. Under the terms of the deal, Curis receives a one-time $14 mil. cash transfer from Stryker, which will amortize the payment over 15 years...
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.